Ignite Creation Date:
2024-05-05 @ 5:03 PM
Last Modification Date:
2024-10-26 @ 9:27 AM
Study NCT ID:
NCT00372944
Status:
COMPLETED
Last Update Posted:
2014-08-13
First Post:
2006-09-05
Brief Title:
AZD6244 vs Capecitabine Xeloda in Patients With Advanced or Metastatic Pancreatic Cancer Who Have Failed First Line Gemcitabine Therapy
Sponsor:
AstraZeneca
Organization:
AstraZeneca
Study Overview
Official Title:
A Phase II Open Randomised Study to Assess the Efficacy and Safety of AZD6244 vs Capecitabine Xeloda in Patients With Advanced or Metastatic Pancreatic Cancer Who Have Failed First Line Gemcitabine Therapy
Status:
COMPLETED
Status Verified Date:
2014-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to assess the efficacy and safety of AZD6244 ARRY-142886versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line therapy with gemcitabine Following baseline assessments a minimum of 64 patients in approximately 5-6 centers from the US will be treated with either AZD6244 or capecitabine Treatment will be continued for as long as the patients receive clinical benefit The status of all patients will be checked whether they are still taking treatment or not approximately 3 months after the last patient has entered the study
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None